IL284156B2 - Anti-CTLA–4 binding proteins and methods of using them - Google Patents

Anti-CTLA–4 binding proteins and methods of using them

Info

Publication number
IL284156B2
IL284156B2 IL284156A IL28415621A IL284156B2 IL 284156 B2 IL284156 B2 IL 284156B2 IL 284156 A IL284156 A IL 284156A IL 28415621 A IL28415621 A IL 28415621A IL 284156 B2 IL284156 B2 IL 284156B2
Authority
IL
Israel
Prior art keywords
seq
antibody
ctla
sequence
cdr3
Prior art date
Application number
IL284156A
Other languages
English (en)
Hebrew (he)
Other versions
IL284156A (en
IL284156B1 (en
Original Assignee
Gigagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gigagen Inc filed Critical Gigagen Inc
Publication of IL284156A publication Critical patent/IL284156A/en
Publication of IL284156B1 publication Critical patent/IL284156B1/en
Publication of IL284156B2 publication Critical patent/IL284156B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL284156A 2018-12-27 2019-12-27 Anti-CTLA–4 binding proteins and methods of using them IL284156B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785659P 2018-12-27 2018-12-27
PCT/US2019/068820 WO2020140084A1 (en) 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof

Publications (3)

Publication Number Publication Date
IL284156A IL284156A (en) 2021-08-31
IL284156B1 IL284156B1 (en) 2024-12-01
IL284156B2 true IL284156B2 (en) 2025-04-01

Family

ID=71126610

Family Applications (2)

Application Number Title Priority Date Filing Date
IL284156A IL284156B2 (en) 2018-12-27 2019-12-27 Anti-CTLA–4 binding proteins and methods of using them
IL316757A IL316757A (en) 2018-12-27 2019-12-27 Anti-CTLA-4 binding proteins and methods of using them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL316757A IL316757A (en) 2018-12-27 2019-12-27 Anti-CTLA-4 binding proteins and methods of using them

Country Status (12)

Country Link
US (2) US12421311B2 (cg-RX-API-DMAC7.html)
EP (1) EP3902821A4 (cg-RX-API-DMAC7.html)
JP (3) JP7558949B2 (cg-RX-API-DMAC7.html)
KR (2) KR102970393B1 (cg-RX-API-DMAC7.html)
CN (2) CN114008071B (cg-RX-API-DMAC7.html)
AU (2) AU2019413366B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012588A2 (cg-RX-API-DMAC7.html)
CA (2) CA3124961C (cg-RX-API-DMAC7.html)
IL (2) IL284156B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007848A (cg-RX-API-DMAC7.html)
SG (1) SG11202106764YA (cg-RX-API-DMAC7.html)
WO (1) WO2020140084A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7296728B2 (ja) * 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
CN114008071B (zh) 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
US20230265192A1 (en) * 2020-07-02 2023-08-24 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
JP2024502035A (ja) * 2020-12-31 2024-01-17 ノヴァロック バイオセラピューティクス, リミテッド Tnfr2に対する抗体およびそれの使用
AU2022303528A1 (en) * 2021-07-02 2024-01-25 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
MX2024007054A (es) * 2021-12-10 2024-09-04 Merck Sharp & Dohme Llc Aglutinantes de mesotelina humana.
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) * 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US20110166335A1 (en) 2000-06-30 2011-07-07 Corbin David R Xenorhabdus sp. genome sequences and uses thereof
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
WO2006029219A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
SMT201900242T1 (it) * 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
WO2015092394A1 (en) 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
PL3151921T3 (pl) * 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
CN114014930A (zh) * 2015-02-13 2022-02-08 索伦托药业有限公司 结合ctla4的抗体治疗剂
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
DK3303394T3 (da) * 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
AU2016370648B2 (en) * 2015-12-15 2023-03-09 OncoC4, Inc. Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
MX2019010156A (es) 2017-02-27 2020-01-09 Dragonfly Therapeutics Inc Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2.
IL270743B2 (en) * 2017-05-19 2024-09-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
CN114008071B (zh) 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
AU2020210614A1 (en) 2019-01-21 2021-08-26 Sanofi Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers
US20230265192A1 (en) 2020-07-02 2023-08-24 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof

Also Published As

Publication number Publication date
EP3902821A4 (en) 2022-11-30
AU2019413366B2 (en) 2025-06-05
EP3902821A1 (en) 2021-11-03
AU2019413366A1 (en) 2021-08-12
BR112021012588A2 (pt) 2021-09-08
CA3249127A1 (en) 2026-03-02
IL284156A (en) 2021-08-31
JP2022516071A (ja) 2022-02-24
JP2024042072A (ja) 2024-03-27
JP2025128343A (ja) 2025-09-02
US20260125474A1 (en) 2026-05-07
AU2025223772A1 (en) 2025-09-18
IL284156B1 (en) 2024-12-01
CN114008071B (zh) 2025-01-21
KR20210121045A (ko) 2021-10-07
CN114008071A (zh) 2022-02-01
WO2020140084A1 (en) 2020-07-02
CA3124961A1 (en) 2020-07-02
SG11202106764YA (en) 2021-07-29
KR102970393B1 (ko) 2026-05-28
CA3124961C (en) 2025-11-25
JP7558949B2 (ja) 2024-10-01
CN119930820A (zh) 2025-05-06
JP7745669B2 (ja) 2025-09-29
JP7854093B2 (ja) 2026-04-30
US20220064303A1 (en) 2022-03-03
US12421311B2 (en) 2025-09-23
KR20260085344A (ko) 2026-06-09
MX2021007848A (es) 2021-10-26
IL316757A (en) 2025-01-01

Similar Documents

Publication Publication Date Title
US20260125474A1 (en) Anti-CTLA-4 Binding Proteins and Methods of Use Thereof
US20220064302A1 (en) Anti-PD-1 Binding Proteins and Methods of Use Thereof
WO2020140094A1 (en) Anti-b7-h3 binding proteins and methods of use thereof
US20230265192A1 (en) Anti-ctla-4 binding proteins and methods of use thereof
WO2020142626A1 (en) Anti-ox40 binding proteins and methods of use thereof
WO2022006555A2 (en) BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
US20220056137A1 (en) Anti-PD-L1 Binding Proteins and Methods of Use Thereof
WO2020140070A1 (en) Anti-b7-h4 binding proteins and methods of use thereof